A research team has conducted an economic evaluation comparing a new drug to an old drug for the reduction of heart attacks in middle-aged (30-60 years) Australian men. Patients in both treatment arms are required to remain on their respective drug for the rest of their lives. The economic evaluation used a healthcare perspective and modelled health benefits to a 50-year time horizon. QALYs were used as an outcome measure. The mean costs of the new drug treatment arm was $11,000 per year for the new drug cost, and $300 per year for all other healthcare resource-use (such as GP visits, hospitalisations etc). The mean costs of the old drug treatment arm was $5,500 per year for the new drug cost, and $900 per year for all other healthcare resource-use. The mean total QALYs in the new drug treatment arm over the 50 years was 41.2 QALYs. The mean total QALYs in the old drug treatment arm over the 50 years was 37.6 QALYs. Part A - Is the time horizon appropriate for this economic evaluation? Why or why not? Part B - Calculate the ICER